Cagrilintide 10mg

Research Specifications

Molecule:
Acylated amylin analog — C20 fatty diacid modification
Developer:
Novo Nordisk
Molecular Weight:
~3800 Da
Vial:
10mg lyophilized (2× the 5mg vial for extended protocols)
Purity:
≥98% HPLC verified

Cagrilintide 10mg

Long-acting amylin analog

CAS: 1415456-99-3

~7 days

Half-life

Clinical PK

−17%

CagriSema Phase 2

Enebo 2021

10mg

Larger vial

~4 weeks at 2.4mg/wk endpoint dose

Receptor Targets

AMY1R/2R/3RArea postrema satiety signaling
CTRCalcitonin receptor (amylin shares binding)
$152.99In Stock
Buy Now
≥98% Purity Verified Free Shipping $200+ HPLC Tested
Phase 3

Phase 3 (CagriSema REDEFINE program)

Novo Nordisk Phase 3 trials ongoing; no approval yet.

Also Known As

AM833CagrilintideAcylated amylin analogCagriSema component

Reconstitution Protocol

BAC Water

2mL

Final Concentration

5 mg/mL

Per Dose

2.4 mg = 0.48 mL · 1.2 mg (titration) = 0.24 mL

Weekly dosing; titrate from 0.25 mg over 12–16 weeks for GI tolerance

Research Stacks

CompoundWhy Researchers Stack It
SemaglutideCagriSema combination — dual pathway satiety
RetatrutideCagri-Reta stack — amylin + triple agonist research

Published References

  1. 1.
    Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide. The Lancet (2021) PMID: 33894838

Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.

Price Comparison

SupplierPurityPriceShipping
our verified supplier>98% HPLC$152.99Free over $200
Generic Research SuppliersVaries (often <95%)Similar–HigherVaries
Pharmaceutical (Rx only)Pharmaceutical gradeNot available for researchRx required

Cagrilintide 10mg

$152.99

Buy Now